Moscow, Moscow, Russian Federation
UDK 615.37 Иммунотерапия (бактериотерапия и т. д.)
This article describes a new method for the synthesis of 2`-O-methoxymethyl monomers applicable for the efficient automated synthesis of 2`-O-modified oligoribonucleotides used for immunotherapy of oncological diseases localized in the gastrointestinal tract.
CpG oligonucleotides, oligoribonucleotides, immunotherapy, oncology
1. Berglof A., Turunen J.J., Gissberg O., Bestas B., Blomberg K.E., Smith S.I. Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Rev. Clin. Immunol. 2013. Vol. 9 (12). P. 1205-1221. DOI:https://doi.org/10.1586/1744666X.2013.850030.
2. Yue X., Q. J. He Chen. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020. Vol. 20:524. DOI:https://doi.org/10.1186/s12935-020-01614-z.
3. Ben-Ali M., Kechout N., Mekki N., et al. Barbouche Genetic Approaches for Definitive Diagnosis of Agammaglobulinemia in Consanguineous Families. J. Clin. Immunol. 2020. Vol. 40(1). P. 96-104. DOI:https://doi.org/10.1007/s10875-019-00706-4. 6.
4. Nijman I.J., Montfrans van J.M., Hoogstraat M., et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J. Allergy Clin. Immunol. 2014. Vol. 133(2). P. 529-534. DOI:https://doi.org/10.1016/j.jaci.2013.08.032.
5. Kanegane H., Hoshino A., Okano T., et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol. Int. 2018. Vol. 67(1). P. 43-54. DOI:https://doi.org/10.1016/j.alit.2017.06.003.
6. Dengjel J., Kratchmarova I., Blagoev B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst. 2009. Vol. 5. № 10. P. 1112-1121. DOI: https://doi.org/10.1039/B909534A.
7. Mohamed A.J., Yu L., Bäckesjö C.M., Vargas L., Faryal R., Aints A., Christensson B., Berglöf A., Vihinen M., Nore B.F., Smith C.I. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainyu. Immunol. Rev. 2009. Vol. 228. №. 1. P. 114-131. DOI: https://doi.org/10.1007/978-3-319-22714-6_5.
8. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011. Vol. 117. № 23. P. 6287-6296. DOI:https://doi.org/10.1182/blood-2011-01-328484.
9. Bernard S., Danglade D., Gardano L., et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int. Journal of Cancer. 2015. Vol. 136. № 12. P. 2761-2774. DOI: https://doi.org/10.1007/978-3-319-18257-5_24.
10. Robak T., Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int. Rev. Immunol. 2013. Vol. 32(4). P. 358-376. DOI:https://doi.org/10.3109/08830185.2013.786711.
